1321515-80-3

Basic information

• Product Name: 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine
• Synonyms: 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine
• CAS NO: 1321515-80-3
• Molecular Weight: 331.3
• Mol File: 1321515-80-3.mol

Chemical Properties

• CAS DataBase Reference: 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine(1321515-80-3)
• EPA Substance Registry System: 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine(1321515-80-3)

Safety Data

• Hazardous Substances Data: 1321515-80-3(Hazardous Substances Data)

Upstream product

• 1620-72-0 2-methyl-6-(trifluoromethyl)pyridine 
• 1321517-51-4 6-bromo-5-phenyl-1,2,4-triazin-3-amine 
• 1321518-03-9 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridine 
• 83413-00-7 3-(methylsulfonyl)-5-phenyl-1,2,4-triazine 
• 942-60-9 5-phenyl-1,2,4-triazin-3-amine 
• 28735-27-5 3-methylthio-5-phenyl-1,2,4-triazine 

Relevant articles and documents

Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design

Potent, ligand efficient, selective, and orally efficacious 1,2,4-triazine derivatives have been identified using structure based drug design approaches as antagonists of the adenosine A2A receptor. The X-ray crystal structures of compounds 4e and 4g bound to the GPCR illustrate that the molecules bind deeply inside the orthosteric binding cavity. In vivo pharmacokinetic and efficacy data for compound 4k are presented, demonstrating the potential of this series of compounds for the treatment of Parkinson's disease.

1,2,4-TRIAZINE-4-AMINE DERIVATIVES

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.